The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Date & Time Volume Price
27.02.23 | 12:14:54 45393 5.25
27.02.23 | 12:13:08 49184 5.25
27.02.23 | 12:11:21 91312 5.25
27.02.23 I 11:41:12. 359601 5.3
Bought more than a handful today. Upcoming events will be truly transformational for the Altona and the company can finally realize some of its hard work - current mcap is laughable!
Grazzyman, now is the time to buy if you are able. 8.1p is holding strong and will act as a springboard to better times ahead. Listing is imminent and Aquis holders deserve a leg up after a disappointing run on the exchange!
Just a thought but if you've been sent something in confidence and it's been leaked, does that then give you the authority to discuss it openly on public forums? Obviously not leaked by you but if I were the broker I would be sending out emails and maybe even removing them from future issues.
Money to be made here for sure but even more over at ANR. Their grades far exceed ours and a tiny mcap of £2m with a move to LSE main market listing to be completed in a hand full of weeks.
FWIW reduced price target!
SIMPLY WALLST
Hello You have 1 new important update for IMM
ImmuPharma
IMM
Share Price 7 Day 1 Year
0.07 -8.8% -28.0%
Price target decreased to UK£0.029
Down from UK£0.036, the current price target is provided by 1 analyst.
New target price is 57% below last closing price of UK£0.067.
Stock is down 28% over the past year.
The company is forecast to post a net loss per share of UK£0.029 next year compared to a net loss per share of UK£0.034 last year.
See Price Chart
BT did not do him or KAV any favours in the way the last KSZ hole and MFC was handled. I was expecting much better from an investigative journalist prospective and it all turned out to be pretty embarrassing both in terms of information available as well as the poor composition of tweets. A fair amount of selling since then as no news of significance due until July at the very earliest.
Numerous deadlines and promised reports quoted on twitter and on previous interviews ignored or negated on. No assay results (that were promised) from any of the previous drills. Welcome to the world of the CEO, investors now expect and you are facing to deliver on your promises. Either stop making any or apply some of the grit he learnt during his investigative journalist days to honour statements made.
Expect plenty more selling to come imo but a quick tick up once we approach July. 2p sp is not unrealistic in the meantime GLA.
As much as I am an avid supporter of ARCM and NvS, Ella has a point on the options.
A crappy and selfish move imho. To reduce dilution was the reason, but only a week later a placing! No doubt used to fund Botswana, ongoing exploration but also those options at 6.94p. Ill-timed at best and should have been done the other way around in order to avoid finger pointing.
Andysmi: Not a P&D imo. This rose on drilling that was anticipated for a decade, on what is expected to be a very attractive asset to the majors and results due in a week, two weeks max. I am a little surprised it is drifting, so time to collect a few more before this multiplies over and over again!
JaySP
"Molopo is mentioned a few times. The deal definitely doesn't sound like a sure thing."
I read through it a couple of times and I am struggling to see where you came up with that theory? Am I to think you maybe are not too keen on acquiring Molopo?